. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009 Dec;66(12):1476-81. PubMed.


Please login to recommend the paper.


  1. All these observations of amyloid deposition in prodromal AD clearly demonstrate that amyloidosis is an early marker of a pathological process that will lead to AD dementia. Accordingly, they also demonstrate that preamyloid, oligomer deposition has not this huge toxicity that makes hot headlines.

    View all comments by Andre Delacourte

Make a Comment

To make a comment you must login or register.